Former President · ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Barry Greene

A named executive officer of ALNYLAM PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$10,348,318

Salary $484,000Stock awards $457,596

FY2019: $3,118,364

1st of 7 named executive officers at Alnylam Pharmaceuticals by FY2020 total.

7 named officers on file for ALNYLAM PHARMACEUTICALS, FY2020

Barry Greene’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 8 equity grants, each cited to its filing
  • ALNY’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ALNYLAM PHARMACEUTICALS’s whole pay program stands against its peers

  • ALNYLAM PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALNY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 2, 2021 (DEF 14A).

Free

Get Barry Greene’s full pay file as a PDF — free

More than this page: up to 10 years of Barry’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barry Greene compensation by year

ALNYLAM PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held
In US dollars, as ALNYLAM PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020
Salary$546,400$562,792$580,000$596,820$484,000
Bonus$0$0$0$0$0
Stock awards$0$0$0$460,360$457,596
Option awards$620,958$0$2,161,275$1,654,494$8,313,010
Non-equity incentive$218,560$365,814$232,000$385,323$376,380
Pension and deferred compensation$0$0$0$0$0
All other$10,195$15,539$21,108$21,367$717,332
Total$1,396,113$944,145$2,994,383$3,118,364$10,348,318

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed April 2, 2021, accession 0001193125-21-105193, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ALNYLAM PHARMACEUTICALS, INC. filed document, accession 0001193125-21-105193. Every figure is read from that document and cited to the page and table it appears in. Filed April 2, 2021.

$1.4M
$944K
$3.0M
$3.1M
$10.3M
FY16
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU16,519$2,146,974—
PSU10,833$1,407,965—
Option18,282—$85.00
Option29,925—$118.05
Option8,182—$119.13
Option10,002—$119.13

Per the Outstanding Equity Awards at Fiscal Year-End table in ALNYLAM PHARMACEUTICALS, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

ALNYLAM PHARMACEUTICALS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Barry Greene · this pageFormer President$10,348,318
John MaraganoreFormer Chief Executive Officer (principal executive officer)$7,818,164
MBChB Yvonne L. GreenstreetPresident and Chief Operating Officer$3,034,001
Akshay VaishnawPresident$2,893,820
Pushkal GargChief Medical Officer and Executive Vice President, Development & Medical Affairs$2,587,750
Jeffrey PoultonExecutive Vice President, Chief Financial Officer$2,492,459
Laurie KeatingExecutive Vice President, Chief Legal Officer and Secretary$2,434,148

The full ALNYLAM PHARMACEUTICALS compensation record

free company brief

This page is one person within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ALNYLAM PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALNYLAM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barry Greene's compensation dossier · One-time report. No refunds.